While modern medicine has advanced, not all drugs do what they intend to do. Sometimes the design of a drug is defective and can cause more harm and pain rather than treating the illness. This typically means the drug was poorly designed and led to unreasonable side effects. A defective drug can cause all types of unexpected side effects, including severe injury or death.
One of these drugs was tofacitinib (Xeljanz, Xeljanz XR) and after a safety trial was conducted by the FDA, they found an increased risk of blood clots in the lungs and even death with rheumatoid arthritis (RA) patients who were prescribed a higher dose.
FDA Warning For Tofacitinib
The FDA wants to inform all prescribed patients about the drug Xeljanz and its risk towards blood clots in the lungs and death. When the FDA first approved tofacitinib, they required a clinical trial among patients with RA to evaluate the risk of heart-related events, cancer, and opportunistic infections with the medicine at two doses (10 mg twice daily and 5 mg twice daily) in combination with methotrexate in comparison to another drug called a tumor necrosis factor (TNF) inhibitor.
The patients that were tested on were required to be 50 years of age and have a cardiovascular risk. During the analysis, the researchers found an increased production of blood clots in the lungs for those patients who were treated with tofacitinib 10 mg twice daily compared to those patients who were treated with tofacitinib 5 mg twice daily.
Even if a drug is FDA-approved and has cleared all safety and quality control measures, it does not mean that the pharmaceutical manufacturer is not liable if complications do arise once it hits the market and more people start to use it. In some cases, mistakes during the manufacturing process can compromise a drug that would have been safe if it was manufactured correctly. In these cases, the manufacturer may be liable for the injuries to patients.
The growth in prescription medication use has led to an increase in unexpected side effects rather than treatment. Those who are affected by dangerous drugs don’t have to suffer alone. Patients are fighting back against negligent drug makers by filing lawsuits and holding them accountable. If you or someone you know has been the victim of a defective pharmaceutical and would like our help, contact KBA Attorneys immediately so our lawyers can help you get the justice you deserve.
Available 24/7/365. No obligation and no cost to you. Se habla español.
Fill out this form for a FREE, immediate, Case Evaluation
Please read these Terms and Conditions ("Terms", "Terms and Conditions") carefully before using the https://www.kbaattorneys.com/ website (the "Service") operated by KBA Attorneys ("us", "we", or "our").
Your access to and use of the Service is conditioned on your acceptance of and compliance with these Terms. These Terms apply to all visitors, users and others who access or use the Service.
By accessing or using the Service you agree to be bound by these Terms. If you disagree with any part of the terms then you may not access the Service. The materials contained in this web site are protected by applicable copyright and trade mark law.
The materials and information contained within the Service is of a general, informational nature but does not constitute legal or professional advice and should not be constituted as such. Use of the Service in any way, does not establish an attorney-client relationship.
Except as required by law, neither KBA Attorneys nor its affiliated firms or businesses accept any responsibility and shall not be liable for any damages (direct, indirect, incidental, special, consequential or exemplary), resulting from the use of this Service. This includes, but is not limited to, damages (for loss of profits, goodwill, use, data or other intangible losses) resulting from the use of or inability to use the Service or its contents or from any interruption or delay in access to the Service for whatever reason.
Note also that sending an e-mail to our office does not create a lawyer-client relationship, and none will be formed unless there is an expressed agreement between the firm and the client. Therefore, we strongly advise you against sending confidential or privileged information to us until you can establish such a relationship.
Our Service may contain links to third-party websites or services that are not owned or controlled by KBA Attorneys
KBA Attorneys has no control over, and assumes no responsibility for, the content, privacy policies, or practices of any third party websites or services. You further acknowledge and agree that KBA Attorneys shall not be responsible or liable, directly or indirectly, for any damage or loss caused or alleged to be caused by or in connection with use of or reliance on any such content, goods or services available on or through any such websites or services.
We strongly advise you to read the terms and conditions and privacy policies of any third-party websites or services that you visit.
These Terms shall be governed and construed in accordance with the laws of Maryland and Virgina, United States, without regard to its conflict of law provisions.
Our failure to enforce any right or provision of these Terms will not be considered a waiver of those rights. If any provision of these Terms is held to be invalid or unenforceable by a court, the remaining provisions of these Terms will remain in effect. These Terms constitute the entire agreement between us regarding our Service, and supersede and replace any prior agreements we might have between us regarding the Service.
We reserve the right, at our sole discretion, to modify or replace these Terms at any time. If a revision is material we will try to provide at least 30 days notice prior to any new terms taking effect. What constitutes a material change will be determined at our sole discretion.
By continuing to access or use our Service after those revisions become effective, you agree to be bound by the revised terms. If you do not agree to the new terms, please stop using the Service.
If you have any questions about these Terms, please contact us.